United Therapeutics initiated with a Buy at UBS

UBS analyst Ashwani Verma initiated coverage of United Therapeutics with a Buy rating and $320 price target. The analyst sees the company’s Tyvaso as a foundational therapy for Pulmonary Arterial Hypertension, and he believes that Tyvaso’s transition into newly launched dry powder inhaler format and expansion into PH-Interstitial Lung Disease fuels growth. Verma adds that United Therapeutics’ Remodulin also has the potential to relatively stabilize going forward, helped by newly relaunched Remunity pump and competitor supply constraints.